Cargando…

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration

IMPORTANCE: Emerging policies drafted by the pharmaceutical industry indicate that they will transparently share clinical trial data. These data offer an unparalleled opportunity to advance evidence-based medicine and support decision-making. OBJECTIVE: To evaluate the eligibility of independent, qu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Modi, Natansh D., Abuhelwa, Ahmad Y., McKinnon, Ross A., Boddy, Alan V., Haseloff, Mark, Wiese, Michael D., Hoffmann, Tammy C., Perakslis, Eric D., Rowland, Andrew, Sorich, Michael J., Hopkins, Ashley M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335250/ https://www.ncbi.nlm.nih.gov/pubmed/35900732 http://dx.doi.org/10.1001/jamaoncol.2022.2867

Ejemplares similares

Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages
por: Hopkins, Ashley M., et al.
Publicado: (2023)

A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies
por: Modi, Natansh D., et al.
Publicado: (2023)

Commentary: Association Between Antihypertensive Medication Use and Breast Cancer: A Systematic Review and Meta-Analysis
por: Modi, Natansh D., et al.
Publicado: (2021)

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data
por: Modi, Natansh D., et al.
Publicado: (2021)

Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib
por: Modi, Natansh D., et al.
Publicado: (2021)

Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine
por: Ang, Fang L.I., et al.
Publicado: (2020)

The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data
por: Modi, Natansh D., et al.
Publicado: (2020)

Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability
por: Hopkins, Ashley M., et al.
Publicado: (2018)

Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer
por: Modi, N.D., et al.
Publicado: (2022)

Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial
por: Hopkins, Ashley M., et al.
Publicado: (2021)

Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2021)

Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176”
por: Hopkins, Ashley M., et al.
Publicado: (2021)

C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2022)

Nuances to precision dosing strategies of targeted cancer medicines
por: Hopkins, Ashley M., et al.
Publicado: (2020)

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
por: Hopkins, Ashley M, et al.
Publicado: (2017)

The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy
por: Badaoui, Sarah, et al.
Publicado: (2022)

Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel
por: Hopkins, Ashley M., et al.
Publicado: (2019)

Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'
por: Rowland, Andrew, et al.
Publicado: (2015)

Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2020)

Data privacy protection in scientific publications: process implementation at a pharmaceutical company
por: Maritsch, Friedrich, et al.
Publicado: (2022)

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
por: Rowland, A, et al.
Publicado: (2015)

Buyouts of Indian Pharmaceutical Companies by Multinational Pharmaceutical Companies: An Issue of Concern
por: Sreedhar, D, et al.
Publicado: (2011)

A clinical scoring tool validated with machine learning for predicting severe hand–foot syndrome from sorafenib in hepatocellular carcinoma
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2022)

Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a post hoc multicohort analysis
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2021)

Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs
por: Daraghmeh, Dala N, et al.
Publicado: (2022)

The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis – a pooled analysis of five randomised controlled trials
por: Manning-Bennett, Arkady T., et al.
Publicado: (2022)

Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies
por: Miller, Jennifer E, et al.
Publicado: (2017)

The influence of pharmaceutical companies
por: Migone, Paolo
Publicado: (2017)

A critical analysis of barriers to the clinical implementation of pharmacogenomics
por: McKinnon, Ross A, et al.
Publicado: (2007)

Audit and Accounting Guide: Investment Companies
por: AICPA
Publicado: (2018)

Pharmaceutical Company Targets and Strategies to Address Climate Change: Content Analysis of Public Reports from 20 Pharmaceutical Companies
por: Booth, Amy, et al.
Publicado: (2023)

Pharmacovigilance in pharmaceutical companies: An overview
por: Mammì, Maria, et al.
Publicado: (2013)

An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins
por: Heinemann, Lutz, et al.
Publicado: (2015)

Pharmacovigilance obligations of the pharmaceutical companies in India
por: Arora, Deepa
Publicado: (2008)

Involvement of pharmaceutical companies at scientific meetings
por: Brink, Andries
Publicado: (2010)

Regulating pharmaceutical companies’ financial largesse
por: Avraham, Ronen, et al.
Publicado: (2018)

The Pharmaceutical Company Approach to Antibiotic Policies
por: White, Anthony R.
Publicado: (2005)

Ethics, gastroenterologists, and pharmaceutical and equipment companies
por: Roberts‐Thomson, Ian C
Publicado: (2020)

Expected Impact of Biosimilars on the Pharmaceutical Companies
por: Golshani, Shiva, et al.
Publicado: (2021)

Medical Affairs in Pharmaceutical Companies and Related Pharmaceutical Regulations in Japan
por: Maeda, Hideki
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ijl45n4ghr4g716qn0kgaa6bvj